Prostate Cancer: New combination active in hormone refractor patient

For patients with hormone refractor prostate cancer a new combination of drugs is showing promise. Avastin which is a new anti angogentic agent, when combine with Emyct and Taxotore has produce response rate up to 77%.

Webmaster

May 24, 2004